A RETROSPECTIVE COHORT STUDY EXAMINING THE SAFETY AND EFFECTIVENESS OF HYDROXYCHLOROQUINE IN PREGNANT INDIVIDUALS WITH IgA NEPHROPATHY

Introduction: Hydroxychloroquine (HCQ) is used in IgA Nephropathy to lower protein levels in the urine (reduce proteinuria) and help protect kidney function. IgA nephropathy (often called IgAN or Berger’s disease) is a kidney disorder where the body’s immune system makes too much of an antibody called immunoglobulin A (IgA). This study compares the kidney health and pregnancy outcomes of pregnant women with IgAN, who took HCQ to those who did not. It also examined whether HCQ is safe for both mother and baby. Methods: A retrospective analysis of singleton gestations and pregnant patients with biopsy-proven IgAN treated at St. Isabel's Hospital from 2022 to 2024 was conducted. Pregnancy outcomes, renal function, and clinical features were compared between women who received and did not receive HCQ.